News & Updates

COVID-19 vaccine-induced immunity PROTECTS BETTER than natural immunity from previous infection

Vaccination against COVID-19 provides superior protection against all-cause health events as shown in a recent study in the US. Vaccinated individuals had significantly lower all-cause mortality, hospitalization, and emergency department visits than those who were previously infected but were unvaccinated.

This suggests that strong natural immunity acquired from a previous COVID-19 infection does not appear to fully compensate for the detrimental effects of an initial infection.

Antifibrotic therapy may confer survival advantage in patients with idiopathic pulmonary fibrosis

The use of antifibrotic therapy in patients with idiopathic pulmonary fibrosis (IPF) has the potential to improve survival outcome, as reported in a study.

Original New Drug Application Approvals by US FDA (16-31 March 2023)

New drug applications approved by US FDA as of 16-31 March 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Biologics lower exacerbation rates in severe asthma, allergic rhinitis

Treatment with either omalizumab (anti-immunoglobulin E [anti-IgE]) or nonomalizumab (non-anti-IgE) biologics reduced exacerbations in patients with severe asthma and allergic rhinitis, with the benefits being more evident among those taking nonomalizumab agents, according to the CHRONICLE trial presented at AAAAI 2023.